Who should read these guidelines?

Essential for medical professionals such as doctors and nurses, as well as care managers and social workers to understand the latest standards in dementia care in Japan.

What are the key updates from the 2017 version?

The 2026 edition includes new disease-modifying therapies like Lecanemab, guidance on COVID-19 related care, and a stronger emphasis on integrated community care and person-centered approaches.

Where can I purchase the book?

Available from May 18, 2026, through Igaku-Shoin's official website, major bookstores across Japan, and online retailers.

AI News NQ Analysis

New 'Dementia Disease Treatment Guidelines 2026' Supervised by Japan Society of Neurology Released on May 18

NQ Score 87/100

N1 Content Completeness 95

AI Summary (NQ-processed)

Igaku-Shoin Ltd. will publish the 'Dementia Disease Treatment Guidelines 2026' on May 18, 2026. This comprehensive update—the first in about 10 years—covers the latest clinical standards, including new anti-amyloid beta antibody drugs, COVID-19 related care, and emphasizes the integration of medical, nursing, and welfare services.

AI Analysis

Frequently Asked Questions

Q: Who should read these guidelines?: A: Essential for medical professionals such as doctors and nurses, as well as care managers and social workers to understand the latest standards in dementia care in Japan.
Q: What are the key updates from the 2017 version?: A: The 2026 edition includes new disease-modifying therapies like Lecanemab, guidance on COVID-19 related care, and a stronger emphasis on integrated community care and person-centered approaches.
Q: Where can I purchase the book?: A: Available from May 18, 2026, through Igaku-Shoin's official website, major bookstores across Japan, and online retailers.